These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

409 related articles for article (PubMed ID: 8896779)

  • 1. Alprazolam premedication and 35% carbon dioxide vulnerability in panic patients.
    Pols H; Verburg K; Hauzer R; Meijer J; Griez E
    Biol Psychiatry; 1996 Nov; 40(9):913-7. PubMed ID: 8896779
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A fixed-dose study of alprazolam 2 mg, alprazolam 6 mg, and placebo in panic disorder.
    Lydiard RB; Lesser IM; Ballenger JC; Rubin RT; Laraia M; DuPont R
    J Clin Psychopharmacol; 1992 Apr; 12(2):96-103. PubMed ID: 1573046
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The speed of onset of action of alprazolam-XR compared to alprazolam-CT in panic disorder.
    Sheehan DV; Sheehan KH; Raj BA
    Psychopharmacol Bull; 2007; 40(2):63-81. PubMed ID: 17514187
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Caffeine and 35% carbon dioxide challenge tests in panic disorder.
    Nardi AE; Valença AM; Lopes FL; de-Melo-Neto VL; Freire RC; Veras AB; Nascimento I; King AL; Soares-Filho GL; Mezzasalma MA; Zin WA
    Hum Psychopharmacol; 2007 Jun; 22(4):231-40. PubMed ID: 17407170
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Double-blind comparison of alprazolam and adinazolam for panic and phobic disorders.
    Pyke RE; Greenberg HS
    J Clin Psychopharmacol; 1989 Feb; 9(1):15-21. PubMed ID: 2651489
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Method for assessing the duration of therapeutic action and milligram equivalence of anxiolytics.
    Sheehan DV; Raj AB; Harnett-Sheehan K; Dorotheo J; Sheehan MF; Trehan R; Knapp E; Swiontek A; Coleman B
    Anxiety; 1996; 2(1):40-6. PubMed ID: 9160598
    [No Abstract]   [Full Text] [Related]  

  • 7. Pharmacologic effect of toloxatone on reactivity to the 35% carbon dioxide challenge: a single-blind, random, placebo-controlled study.
    Perna G; Cocchi S; Bertani A; Arancio C; Bellodi L
    J Clin Psychopharmacol; 1994 Dec; 14(6):414-8. PubMed ID: 7884022
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A double-blind study of the efficacy of venlafaxine extended-release, paroxetine, and placebo in the treatment of panic disorder.
    Pollack MH; Lepola U; Koponen H; Simon NM; Worthington JJ; Emilien G; Tzanis E; Salinas E; Whitaker T; Gao B
    Depress Anxiety; 2007; 24(1):1-14. PubMed ID: 16894619
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Alprazolam, propranolol, and placebo in the treatment of panic disorder and agoraphobia with panic attacks.
    Munjack DJ; Crocker B; Cabe D; Brown R; Usigli R; Zulueta A; McManus M; McDowell D; Palmer R; Leonard M
    J Clin Psychopharmacol; 1989 Feb; 9(1):22-7. PubMed ID: 2651490
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Abrupt discontinuation of alprazolam and cognitive style in patients with panic disorder: early effects on mood, performance, and vital signs.
    Uhlenhuth EH; Starcevic V; Qualls C; Antal EJ; Matuzas W; Javaid JI; Barnhill J
    J Clin Psychopharmacol; 2006 Oct; 26(5):519-23. PubMed ID: 16974197
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A controlled study of alprazolam and propranolol in panic-disordered and agoraphobic outpatients.
    Ravaris CL; Friedman MJ; Hauri PJ; McHugo GJ
    J Clin Psychopharmacol; 1991 Dec; 11(6):344-50. PubMed ID: 1770152
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Benzodiazepine treatment of panic disorder: a comparison of alprazolam and lorazepam.
    Charney DS; Woods SW
    J Clin Psychiatry; 1989 Nov; 50(11):418-23. PubMed ID: 2808308
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Personality dimensions in panic disorder before and after effective treatment.
    Starcevic V; Uhlenhuth EH
    Anxiety; 1996; 2(2):95-8. PubMed ID: 9160608
    [No Abstract]   [Full Text] [Related]  

  • 14. Treatment of panic disorder.
    Cassano GB; Toni C; Musetti L
    Adv Biochem Psychopharmacol; 1992; 47():449-60. PubMed ID: 1509926
    [No Abstract]   [Full Text] [Related]  

  • 15. Efficacy of alprazolam sublingual tablets in the treatment of the acute phase of panic disorders.
    Márquez M; Arenoso H; Caruso N
    Actas Esp Psiquiatr; 2011; 39(2):88-94. PubMed ID: 21404147
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The efficacy and safety of alprazolam versus other benzodiazepines in the treatment of panic disorder.
    Moylan S; Staples J; Ward SA; Rogerson J; Stein DJ; Berk M
    J Clin Psychopharmacol; 2011 Oct; 31(5):647-52. PubMed ID: 21869686
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Clinical picture and treatment of agoraphobia with panic disorder].
    Litvintsev SV; Reznik AM; Kvashnina NV; Arbuzov AL; Krylov KE
    Voen Med Zh; 2003 Jun; 324(6):53-9. PubMed ID: 12916423
    [No Abstract]   [Full Text] [Related]  

  • 18. Anxiolytic therapy with alprazolam increases muscle sympathetic activity in patients with panic disorders.
    Béchir M; Schwegler K; Chenevard R; Binggeli C; Caduff C; Büchi S; Buddeberg C; Lüscher TF; Noll G
    Auton Neurosci; 2007 Jul; 134(1-2):69-73. PubMed ID: 17363337
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Diazepam versus alprazolam for the treatment of panic disorder.
    Noyes R; Burrows GD; Reich JH; Judd FK; Garvey MJ; Norman TR; Cook BL; Marriott P
    J Clin Psychiatry; 1996 Aug; 57(8):349-55. PubMed ID: 8752017
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Alprazolam plasma concentrations and treatment response in panic disorder and agoraphobia.
    Lesser IM; Lydiard RB; Antal E; Rubin RT; Ballenger JC; DuPont R
    Am J Psychiatry; 1992 Nov; 149(11):1556-62. PubMed ID: 1415824
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.